tiprankstipranks
Iterum Therapeutics Plc (ITRM)
NASDAQ:ITRM
US Market

Iterum Therapeutics Stock Analysis & Ratings

ITRM Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.18 - $1.63
Previous Close$0.21
Volume1.15M
Average Volume (3M)1.18M
Market CapN/A
Enterprise ValueN/A
P/E Ratio9.8
Beta1.17
Next EarningsAug 12, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
1Y Price TargetN/A
Smart Score5


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

ITRM FAQ

What was Iterum Therapeutics’s price range in the past 12 months?
Iterum Therapeutics lowest stock price was $0.17 and its highest was $1.63 in the past 12 months.
    What is Iterum Therapeutics’s market cap?
    Currently, no data Available
    What is Iterum Therapeutics’s price target?
    Currently, no data Available
    What do analysts say about Iterum Therapeutics?
    Iterum Therapeutics’s analyst rating consensus is a ‘Hold. This is based on the ratings of 1 Wall Streets Analysts.
      When is Iterum Therapeutics’s upcoming earnings report date?
      Iterum Therapeutics’s upcoming earnings report date is Aug 12, 2022 which is in 40 days.
        How were Iterum Therapeutics’s earnings last quarter?
        Iterum Therapeutics released its earnings results on May 13, 2022. The company reported -$0.03 earnings per share for the quarter, beating the consensus estimate of -$0.04 by $0.01.
          Is Iterum Therapeutics overvalued?
          According to Wall Street analysts Iterum Therapeutics’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Iterum Therapeutics pay dividends?
            Iterum Therapeutics does not currently pay dividends.
            What is Iterum Therapeutics’s EPS estimate?
            Iterum Therapeutics’s EPS estimate is -$0.06.
              How many shares outstanding does Iterum Therapeutics have?
              Iterum Therapeutics has 183,353,420 shares outstanding.
                What happened to Iterum Therapeutics’s price movement after its last earnings report?
                Iterum Therapeutics reported an EPS of -$0.03 in its last earnings report, beating expectations of -$0.04. Following the earnings report the stock price went up 10%.
                  Which hedge fund is a major shareholder of Iterum Therapeutics?
                  Among the largest hedge funds holding Iterum Therapeutics’s share is New Leaf Venture Partners, L.L.C.. It holds Iterum Therapeutics’s shares valued at 517K.

                    ---

                    Iterum Therapeutics Stock Analysis

                    Smart Score
                    5
                    Neutral
                    1
                    2
                    3
                    4
                    5
                    6
                    7
                    8
                    9
                    10
                    Price Target
                    No data currently available
                    The Iterum Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                    Learn more about TipRanks Smart Score

                    Company Description

                    Iterum Therapeutics Plc

                    Iterum Therapeutics Plc is a clinical-stage pharmaceutical company, which engages in the development and commercialization of treatments for drug resistant bacterial infections. It focuses on sulopenem program that offer a solution to the problem of antibiotic resistance, and the toxicity limitations of existing agents. It operates through the Ireland and Unites States geographical segments. The company was founded by Corey N. Fishman on June 24, 2015 and is headquartered in Dublin, Ireland.

                    ---
                    Similar Stocks
                    Company
                    Price & Change
                    Follow
                    Aslan Pharmaceuticals
                    RVL Pharmaceuticals
                    Kezar Life Sciences
                    Xeris Pharmaceuticals
                    Verona Pharma

                    Popular Stocks

                    ---
                    What's Included in PREMIUM?
                    Make informed decisions based on Top Analysts' activity
                    Know what industry insiders are buying
                    Get actionable alerts from top Wall Street Analysts
                    Find out before anyone else which stock is going to shoot up
                    Get powerful stock screeners & detailed portfolio analysis